Heparin‐induced thrombocytopaenia · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Live birth · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin may leads to higher live birth compared with aspirin (low certainty).
1 finding from 1 review
Pre‐eclampsia · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin showed no clear difference in pre‐eclampsia compared with aspirin (low certainty).
1 finding from 1 review
Adverse events in the mother ‐ Bleeding · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin showed no clear difference in adverse events in the mother ‐ Bleeding compared with aspirin (low certainty).
1 finding from 1 review
Allergic reaction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Venous thromboembolism · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Arterial thromboembolism · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Pregnancy loss · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
Heparin plus aspirin may leads to lower pregnancy loss compared with aspirin (low certainty).
1 finding from 1 review
Preterm delivery of a live infant · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether heparin plus aspirin changes preterm delivery of a live infant compared with aspirin (very low certainty).
1 finding from 1 review
Intrauterine growth restriction · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
It is very uncertain whether heparin plus aspirin changes intrauterine growth restriction compared with aspirin (very low certainty).
1 finding from 1 review
Adverse events in the child ‐ Congenital malformations · women with persistent antiphospholipid antibodies and recurrent pregnancy loss
1 finding from 1 review
Maternal death · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic thromboembolic events ( · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic thromboembolic events ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic PE ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes symptomatic DVT ( compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · pregnant women at increased risk of VTE during pregnancy and the early postnatal period
It is very uncertain whether antenatal (± postnatal) prophylaxis: heparin (LMWH or UFH) changes adverse effects sufficient to stop treatment compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Maternal death · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review
Symptomatic thromboembolic events ( · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic thromboembolic events (timing of assessment unclear,… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic PE · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
It is very uncertain whether peripartum/postnatal prophylaxis (caesarean): heparin (LMWH or UFH) changes symptomatic PE (timing of assessment unclear, within 6 weeks… compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Symptomatic DVT · women giving birth by elective or emergency caesarean (elective only (1 trial), emergency or elective (4 trials))
1 finding from 1 review